The mission of the University of Maryland Marlene and Stewart Greenebaum Cancer Center is to undertake innovative basic and clinical research which will impact the understanding and treatment of cancer around the world and to provide state-of-the-art clinical care to cancer patients in Maryland and beyond. Our strategy is to take advantage of discoveries in basic cancer biology in conjunction with clinical research to: * Develop and apply innovative therapeutic and preventive strategies to cancer patients. * Describe the molecular mechanisms involving specific clinical phenotypes and behaviors. * Apply the above discoveries and strategies to the Maryland community with a specific focus on cancer disparities. In this application, the UMGCC seeks NCI designation as a clinical cancer center to support its stated mission. Since the previous CCSG application in 2002, the UMGCC has undertaken an historic expansion representing an investment of more than $100 million, providing state-of-the-art clinical and research facilities equipment and supporting the recruitment of outstanding faculty from across the country. In the present application, the UMGCC is represented by 152 members working in three full and two developing research programs with four full and four developing shared services. The UMGCC provides an effective umbrella supporting the multidisciplinary cancer research activities of this talented group of investigators. Total cancer funding has risen from $25.7 million in 2002 to $47.1 million in 2007. In FY07, the UMGCC served more than 2,000 new cancer patients and handled 33,006 outpatient visits, 9,898 infusion visits, 1,444 inpatient admissions. During FY07, 976 patients participated in 150 enrolling clinical trials. Remarkably, 37% of clinical trial participants in FY07 were under represented minorities, reflecting UMGCC's unique position and mission to involve the minority community in state-of-the-art clinical/translational research and to provide state-of-the-art care for a historically disadvantaged population with a high cancer burden. UMGCC researchers have made outstanding contributions to our understanding of cancer biology and important recent work from our laboratories and clinics is now the standard of care worldwide. Reflecting our remarkable recent growth, the UMGCC seeks CCSG support to enhance and expand its efforts in high quality and clinically relevant cancer research.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA134274-02S2
Application #
7926266
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
2009-09-01
Project End
2011-08-31
Budget Start
2009-09-01
Budget End
2011-08-31
Support Year
2
Fiscal Year
2009
Total Cost
$150,000
Indirect Cost
Name
University of Maryland Baltimore
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
188435911
City
Baltimore
State
MD
Country
United States
Zip Code
21201
Wang, Junxiang; Zhao, Liang; Ye, Yanfang et al. (2018) Adverse event detection by integrating twitter data and VAERS. J Biomed Semantics 9:19
Furusawa, Aki; Reiser, John; Sadashivaiah, Kavitha et al. (2018) Eomesodermin Increases Survival and IL-2 Responsiveness of Tumor-specific CD8+ T Cells in an Adoptive Transfer Model of Cancer Immunotherapy. J Immunother 41:53-63
Nathenson, Michael J; Conley, Anthony P; Sausville, Edward (2018) Immunotherapy: A New (and Old) Approach to Treatment of Soft Tissue and Bone Sarcomas. Oncologist 23:71-83
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Exploring the effect of library preparation on RNA sequencing experiments. Genomics :
Nathenson, Michael J; Barysauskas, Constance M; Nathenson, Robert A et al. (2018) Surgical resection for recurrent retroperitoneal leiomyosarcoma and liposarcoma. World J Surg Oncol 16:203
Sallmyr, Annahita; Tomkinson, Alan E (2018) Repair of DNA double-strand breaks by mammalian alternative end-joining pathways. J Biol Chem 293:10536-10546
Kerr, Candace; Adhikary, Gautam; Grun, Daniel et al. (2018) Combination cisplatin and sulforaphane treatment reduces proliferation, invasion, and tumor formation in epidermal squamous cell carcinoma. Mol Carcinog 57:3-11
Connolly, Sean; Quasi-Woode, Devona; Waldron, Laura et al. (2018) Calcineurin Regulatory Subunit Calcium-Binding Domains Differentially Contribute to Calcineurin Signaling in Saccharomyces cerevisiae. Genetics 209:801-813
Pauza, C David; Liou, Mei-Ling; Lahusen, Tyler et al. (2018) Gamma Delta T Cell Therapy for Cancer: It Is Good to be Local. Front Immunol 9:1305
Wang, Lei; Felts, Sara J; Van Keulen, Virginia P et al. (2018) Integrative Genome-Wide Analysis of Long Noncoding RNAs in Diverse Immune Cell Types of Melanoma Patients. Cancer Res 78:4411-4423

Showing the most recent 10 out of 257 publications